Many studies have attempted to explain the interindividual variability observed in drug
metabolism by assessing the impact of SNPs in genes implicated in drug absorption …

The highly variable pharmacokinetics of tacrolimus can hamper the optimal management of
kidney transplant patients. This variability has been attributed to the genetic polymorphism of …

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature
for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus …

With current treatment regimens, a relatively high proportion of transplant recipients
experience underimmunosuppression or overimmunosuppression. Recently, several …

The number of older adults undergoing kidney transplantation has increased, yet little is
known about calcineurin inhibitor (CNI) metabolism in this group. We studied CNI troughs …

Background: A large number of clinical studies have documented that a loss‐of‐function
variant CYP2C19* 2 affects clinical profiles of clopidogrel (efficacy and safety). However …

Cyclosporine, everolimus, and tacrolimus are the cornerstone of immunosuppressive
therapy in renal transplantation. These drugs are characterized by narrow therapeutic …

In association with therapeutic drug monitoring of immunosuppressive drugs,
pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or …

Background CYP3A5 genetic polymorphisms contribute to marked interindividual
differences in the metabolism of and response to tacrolimus in humans. Objective This study …

BACKGROUND: The published data revealed conflicting results of the polymorphism of
MDR1 exon 26 SNP C3435T on the pharmacokinetics of tacrolimus in different post …